425: Ikena Oncology Merger with Inmagene Biopharmaceuticals Gains Key Proxy Firm Endorsements

Ikena Oncology announced that leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass, Lewis & Co., recommend stockholders vote FOR the proposed merger with Inmagene Biopharmaceuticals.

Summary

• Ikena Oncology, Inc. is proceeding with a previously announced merger with Inmagene Biopharmaceuticals, an exempted company incorporated in the Cayman Islands.
• The merger involves a two-step process where Ikena's direct wholly-owned subsidiaries, Merger Sub I and Merger Sub II, will merge with and into Inmagene, resulting in Inmagene becoming a direct, wholly-owned subsidiary of Ikena.
• Institutional Shareholder Services (ISS) and Glass, Lewis & Co. have recommended that Ikena stockholders vote FOR the issuance of shares related to the merger at the upcoming Annual Meeting of Stockholders.
• The Annual Meeting of Stockholders is scheduled for July 15, 2025, where stockholders as of the record date of May 22, 2025, are entitled to vote.
• Inmagene Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on immunological and inflammatory (I&I) diseases, with its lead asset being IMG-007.
• IMG-007 is a nondepleting anti-OX40 monoclonal antibody (mAb) engineered for minimized safety risks and prolonged half-life, potentially enabling less frequent dosing regimens.
• IMG-007 recently completed a Phase 2a clinical trial in patients with moderate-to-severe atopic dermatitis, demonstrating marked and durable clinical activity and a well-tolerated safety profile.
• The company has also begun treating the first patients in a global Phase 2B study for IMG-007 in atopic dermatitis.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the strong recommendations from leading proxy advisory firms for the proposed merger, which is a critical step towards its completion. Additionally, positive clinical progress for Inmagene's lead asset, IMG-007, further contributes to the positive outlook.

Positives

• Leading independent proxy advisory firms, ISS and Glass Lewis, recommend a 'FOR' vote for the share issuance related to the merger, indicating strong institutional support.
• Inmagene's lead asset, IMG-007, a nondepleting anti-OX40 mAb, has shown promising results in a recently completed Phase 2a trial for moderate-to-severe atopic dermatitis, demonstrating marked and durable clinical activity and a well-tolerated safety profile.
• IMG-007's subcutaneous formulation has a prolonged half-life of 34.7 days, which could enable competitive and less frequent dosing regimens, such as potentially Q24W dosing in the maintenance phase for atopic dermatitis.
• The initiation of a global Phase 2B study for IMG-007 in atopic dermatitis signifies advancement in its clinical development.

Risks

• Conditions to the closing of the Merger may not be satisfied, including the failure to timely obtain stockholder approval for the Merger Agreement and related transactions.
• Uncertainties exist regarding the timing of the consummation of the proposed Merger and the ability of Ikena and Inmagene to complete it.
• Risks related to Ikena's ability to manage its operating expenses and expenses associated with the proposed Merger pending its closing.
• Failure or delay in obtaining required approvals from governmental or quasi-governmental entities necessary to consummate the proposed Merger.
• Adjustments to the exchange ratio could result in Ikena stockholders and Inmagene shareholders owning more or less of the combined company than currently anticipated.
• Risks related to the market price of Ikena common stock relative to the value suggested by the exchange ratio.
• Potential for unexpected costs, charges, or expenses resulting from the transaction.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger.
• Uncertainties associated with Inmagene's platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment, and completion of clinical trials.
• Risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance product candidates and preclinical programs.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Risks related to the failure to realize any value from product candidates and preclinical programs being developed due to inherent risks and difficulties in bringing them to market.
• Risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results and increasing stockholder value.
• Risks associated with Ikena's financial close process.
• The risk that the Ikena concurrent financing is not consummated.
• The potential for the occurrence of any event, change, or other circumstance or condition that could give rise to the termination of the Merger Agreement and any related agreements.
• The possibility that contingent value rights holders of Ikena and Inmagene may never receive any proceeds pursuant to their respective contingent value rights agreements.

Future Outlook

The combined company is expected to be listed on Nasdaq after the merger's closing, with anticipated future operations focused on developing product candidates and platform technologies, particularly in immunological and inflammatory diseases. Management anticipates continued preclinical and clinical drug development activities, including the global Phase 2B study for IMG-007, and expects to realize certain benefits from the merger, including potential shareholder value creation. The combined company's cash position and runway following the merger and concurrent financing are also a key forward-looking consideration.

Management Comments

• Mark Manfredi, Ph.D., Chief Executive Officer of Ikena, commented that IMG-007 has notable potential to build value for shareholders across the I&I space, and the Ikena Board is encouraged and remains committed to the merger with Inmagene given recent progress in the global Phase 2B study and advancements across I&I.

Industry Context

This announcement reflects a strategic consolidation within the biopharmaceutical sector, specifically targeting the immunological and inflammatory (I&I) disease space. The merger aims to combine Ikena's oncology focus with Inmagene's I&I pipeline, particularly leveraging IMG-007, an anti-OX40 monoclonal antibody. The positive recommendations from proxy advisory firms are crucial for securing shareholder approval, a common hurdle in biopharma M&A, and indicate institutional confidence in the strategic rationale.

Stakeholder Impact

• Shareholders: Will vote on the merger, potentially impacting their ownership structure and the future value of their investment in the combined entity. The proxy firm recommendations are intended to guide their voting decision.
• Employees: The merger will lead to the formation of a combined company, potentially affecting roles, responsibilities, and organizational structure.
• Patients: The combined company aims to advance product candidates, particularly IMG-007 for atopic dermatitis, potentially offering new therapeutic options for patients with immunological and inflammatory diseases.

Next Steps

• Ikena's Annual Meeting of Stockholders to be held on July 15, 2025, for stockholders to vote on the share issuance related to the merger and other proposals.
• Completion of the proposed merger between Ikena Oncology and Inmagene Biopharmaceuticals, subject to satisfaction or waiver of conditions and stockholder approval.
• Potential consummation of the Ikena concurrent financing.

Key Dates

Recommendation

Keywords

Merger, Biopharmaceuticals, Oncology, Immunology, Inflammation, Clinical Stage, Drug Development, Proxy Vote, Shareholder Meeting, SEC Filing, Atopic Dermatitis, OX40, Monoclonal Antibody, IKNA